表达MATE的瘤病毒促进瘤中目标独立的T细胞激活
Malin Peter1, Bettina Mundt1, Arne Menze1
1Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
EMBO molecular medicine
|January 9, 2025
概括
新型瘤病毒 (OVs) 在广泛的瘤免疫疗法中表达膜相关的T细胞参与因子 (MATEs). 这种方法增强T细胞激活,减少瘤生长,克服对检查点治疗的抗性.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 在瘤学瘤学.
背景情况:
- 表达双特异性T细胞参与因子 (BiTEs) 的瘤病毒 (OV) 在瘤免疫疗法中表现有前途,但瘤向性有限.
- 有效的T细胞刺激对于在癌症治疗中广泛应用至关重要.
研究的目的:
- 开发和评估与膜相关的T细胞激活剂 (MATEs),以增强T细胞激活和广泛的瘤免疫治疗.
- 评估MATE表达性OVs在减少瘤生长和克服对检查点治疗的抗性方面的有效性.
主要方法:
- 已建立的MATE使用HIV-Tat蛋白转导域进行非选择性结合.
- 在MC38瘤模型中利用瘤性腺病毒Ad5/11来表达MATE.
- 评估了T细胞激活,瘤杀死,瘤生长,存活率和免疫细胞透在体外和体内.
主要成果:
- 在实验室中,MATE有效地激活了小鼠和人类T细胞.
- 在小鼠中,表达MATE的Ad5/11降低了MC38瘤生长,延长了存活时间,并增加了内CD8+T细胞.
- 通过Ad5/11的MATE表达克服了对αPD-1检查点治疗的抗性.
- 淋巴结中早期T细胞激活的缺失表明安全的适用性.
结论:
- 表达MATE的OVs是局部瘤免疫治疗的有效工具.
- 这一策略促进了广泛的T细胞激活和广泛适用于各种瘤.
- 表达MATE的OV可以增强现有的癌症免疫疗法的疗效.
关键词:
CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD4 CD4 CD4 CD4 CD4 CD5 CD5 CD5 CD5 CD5 CD6 CD7 CD7 CD7 CD7 CD7 CD7 CD7 CD7 CD7 CD8 CD7 CD8 CD8 CD8 CD8 CD8 CD9在数学上,数学就是数学.瘤性腺病毒 (Adenovirus) 是一种致癌病毒.这种T细胞激活剂是T细胞激活剂.这就是Tat-PTDD.更多相关视频
10:01Radial Mobility and Cytotoxic Function of Retroviral Replicating Vector Transduced, Non-adherent Alloresponsive T Lymphocytes
Published on: February 11, 2015
7.7K
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
21.3K
相关概念视频
Tumor Immunotherapy
472
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
472
Cytotoxic T Cells-mediated Immune Response
841
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
841
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
